Search

Search Constraints

You searched for: Author/Creator Carducci, Michael

Search Results

1. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Issue 10032 (14th May 2016)

2. Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805. Issue 12 (10th May 2022)

4. Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Issue 1 (14th March 2019)

5. Does Valproic Acid Induce Neuroendocrine Differentiation in Prostate Cancer?. (25th October 2010)

8. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial. Issue 18 (16th July 2020)

9. PACCT: an intervention to increase clinical trial invitations for Black and White men with cancer: Presenter(s): Lauren Hamel, Wayne State University/Karmanos Cancer Institute, United States. (April 2023)

10. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Issue 6 (20th February 2023)